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Introduction
Neurofibromas and schwannomas are benign tumours of 
the peripheral nerve sheath. They are encountered within 
a wide range of medical specialities and may occur as iso-
lated sporadic lesions or as a key feature of genetic disorders 
including schwannomatosis, neurofibromatosis type 1 (NF1) 
and neurofibromatosis type 2 (NF2). Approximately half of 
cases of NF1 and NF2 are the result of autosomal dominant 
inheritance of a germline mutation from an affected parent, 
whilst the remainder are caused by de novo mutations. NF1 
is caused by mutations in the NF1 gene on chromosome 
17q11.2, and NF2 is caused by mutation of the NF2 gene 
at locus 22q12.2. Despite considerable phenotypic overlap 
with NF2, schwannomatosis has been shown to a distinct 
entity with pathological variants in SMARCB1 and LZTR1 
genes. NF1 is the most common of the three conditions, with 
a frequency of 1 in 2500–3000 live births, whereas NF2 and 
schwannomatosis are considerably less common.
Each of these disorders has a distinct clinical profile. NF1 
is predominantly neurocutaneous, characterised by neurofi-
bromas, with concomitant eye and bone manifestations. NF2 
is a central disorder, with tumours occurring in cranial and 
spinal nerves, most commonly bilateral vestibular schwan-
nomas. The characteristic presentation of schwannomatosis 
is with chronic pain associated with cutaneous and central 
schwannomas, but without the other features of NF1 or 
NF2. The nature of these disorders results in overlap in care 
between neurology, dermatology and genetics and current 
management is largely symptomatic and surgical, with effec-
tive disease modifying treatments remaining elusive.
In this month’s journal club we review two articles relat-
ing to these conditions: a study providing insights into the 
epidemiology of schwannomatosis and NF2, and a phase 1 
study examining the use of a selective inhibitor of mitogen-
activated protein kinase (MAPK).
Schwannomatosis: a genetic 
and epidemiological study
NF2 and schwannomatosis are rare genetic disorders that 
predispose to the formation of spinal and peripheral nerve 
schwannomas and have considerable clinical overlap. 
Although the presence of vestibular schwannomas (VS) in 
NF2 has previously been considered a distinguishing feature, 
it is now recognized that LZTR1 schwannomatosis can be 
associated with VS. The potential for misdiagnosis is clear 
and population-based epidemiological data scarce, prompt-
ing this study.
A national (UK) NF2 and schwannomatosis database was 
interrogated to identify patients meeting existing diagnostic 
criteria. All patients underwent DNA sequencing and Mul-
tiple Ligation dependent Probe Amplification (MLPA) of 
the NF2 gene as well as sequencing and MLPA for LZTR1 
and SMARCB1 genes (known to be associated with familial 
schwannomatosis). Tumour samples, where available, were 
also screened in patients for whom no pathogenic mutation 
was identified. Epidemiological data were determined both 
from a highly ascertained regional cohort and within the 
national population, and clinical phenotypes were compared.
A total of 1192 patients met criteria for NF2 and 399 for 
schwannomatosis. Within the strict regional boundaries of 
a highly ascertained nested study there were 95 NF2 and 
44 schwannomatosis cases. Regional point prevalence was 
estimated as 1:50,000 and 1:126,135, respectively. Birth 
incidence was 1:27,965 for NF2 and 1:68,956 for schwan-
nomatosis. Pathological mutations in LZTR1 were found to 
account for 16% of the regional cases (and 18.5% of national 
cases), while mutations in SMARCB1 accounted for 25% of 
cases regionally (12.5% nationally). A further 4% (3%) of 
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cases had mosaic NF2 and in 50% (67%) no pathogenic vari-
ant was identified. In the local cases designated as NF2, 2% 
(0.5%) had an LZTR1 mutation, 0% (0%) had SMARCB1, 
52% (49.5%) had a full constitutional NF2 pathogenic vari-
ant and in 21% (35%) no pathogenic variant was identified.
In terms of clinical features NF2 had a significantly lower 
mean life expectancy of 66.2 years compared to 76.9 for 
schwannomatosis. Apart from the expected excess of VS 
in people with NF2, they also had significantly more non-
vestibular cranial schwannomas than people with schwanno-
matosis. However, people with schwannomatosis had more 
peripheral and spinal nerve schwannomas and pain was a 
predominant presenting symptom.
Comment Generating confident epidemiological statistics 
such as these are difficult to accomplish in very low fre-
quency disease. The size of the cohorts in this study provide 
useful clinical and genetic insights into both schwannomato-
sis and NF2 as well as an important caution about the clini-
cal overlap between these conditions. However, analysis of 
both national and regional patient groups does provide some 
variation that at times is difficult to interpret and the data 
presented would benefit from confidence intervals. Lastly, 
the large gap in precise genetic diagnoses in these conditions 
is highlighted with no pathogenic mutation identified in a 
considerable number of people who were clinically labelled 
as having NF2 or schwannomatosis.
J Neurol Neurosurg Psychiatry. 2018 Jun 16. [Epub 
ahead of print]
Activity of selumetinib in neurofibromatosis 
type 1‑related plexiform neurofibromas
The majority of patients with NF1 develop central and 
peripheral nerve sheath tumours caused by a lack of func-
tioning neurofibromin which leads to dysregulation of Ras 
proteins (a family of proteins controlling cell signalling path-
ways and tumourigenesis). The development of plexiform 
neurofibromas in 20–50% of people with NF1 is attributed 
to elevated Ras-MAPK signalling. These tumours can cause 
significant complications including physical deformities, 
functional decline, pain, malignant transformation as well as 
cognitive and behavioural changes. At present, no effective 
medical treatment is available for plexiform neuromas and 
clinical management is largely centred around surveillance 
and symptom-guided surgical intervention, with complete 
resection frequently unfeasible. The advent of agents that 
target Ras signalling has opened up a potential therapeutic 
opportunity for NF1.
This study was a phase 1 trial of selumetinib, an oral 
selective inhibitor of MAPK kinase (MAP2K or MEK) 1 
and 2. Selumetinib mitigates the downstream effects of up-
regulation of Ras activity due to NF1 mutations, and has 
already shown activity against advanced thyroid cancer, 
NSCLC and melanomas in adults in separate trials.
Twenty-four children aged 3–18 years (median 10.9) with 
a clinical diagnosis of NF1 and who had inoperable, measur-
able, plexiform neurofibromas that had potential to cause sig-
nificant complications were included in the trial. Selumetinib 
(10 mg and 25 mg capsules) was administered approximately 
every 12 h on a continuous dosing schedule in 28-day cycles. 
Dose was calculated using body-surface area, starting with 
20 mg per square metre and up to 50 mg per square metre. 
Patient assessments included a range of clinical examina-
tions, laboratory evaluations, ophthalmologic examinations, 
echocardiography, and electrocardiography at baseline and at 
regular intervals. MRI images of tumours were obtained with 
volumetric analysis at baseline, after cycles 5 and 10, and 
then after every 6 subsequent cycles. The number of cycles 
of selumetinib administered ranged from 6 to 56 (median 
30);19 patients received more than 30 cycles.
Selumetinib was well tolerated up to 25 mg per square 
metre every 12 h when taken over the long-term (median 
120 weeks). Common side-effects included acneiform rash, 
gastro-intestinal upset and asymptomatic creatine kinase 
elevation. The most common dose-limiting toxic effects 
were mucositis, aminotransferase elevation, decreased neu-
trophil count, and paronychia. A reversible dose-dependent 
decrease in left ventricular function was seen in one patient. 
Five patients withdrew from treatment, 1 as a result of dose-
limiting toxic effects.
Partial response, defined by a tumour volume decrease 
of ≥ 20% from baseline, was observed in 17 of the 24 chil-
dren (71%). Disease progression defined as a ≥ 20% volume 
increase from baseline was not observed. Data on additional 
clinical benefits were not routinely collected, however, anecdo-
tal evidence suggested that individual patients benefited from 
reductions in pain, degree of disfigurement and motor function. 
A parallel pharmacokinetic and pre-clinical study undertaken 
in a murine model of NF1 demonstrated a decrease in neurofi-
broma volume in 12 of 18 NF1 mice (67%) versus an increase 
of neurofibroma volume in 14 of the 15 control animals.
Comment These are preliminary results and require vali-
dation in larger studies, which should include qualitative 
analysis of any clinical improvements resulting from volu-
metric reduction of neurofibromas. However, these data indi-
cate the potential for effective short- to medium-term tumour 
control in a disease which has hitherto been extremely dif-
ficult to manage and highly distressing for patients.
N Engl J Med. 2016 Dec 29;375(26):2550–2560
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